RBN013209
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].
Product Specifications
CAS Number
[2597933-17-8]
UNSPSC
12352005
Target
CD38; LAG-3; PD-1/PD-L1; Tim3
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rbn013209.html
Concentration
10mM
Purity
98.63
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COCCO[C@@H](CC1)CC[C@H]1NC(C2=C3C(C=CN3)=NC(N4C=CN=C4)=N2)=O
Molecular Formula
C19H24N6O3
Molecular Weight
384.43
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-144987/RBN013209-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-144987/RBN013209-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items